查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541790

2024-2032 年按治療類型（藥物類別、微創手術、雷射治療等）和地區分類的良性前列腺增生治療市場報告

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type (Drug Class, Minimally Invasive Surgeries, Laser Therapy, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球良性前列腺增生治療市場規模達119億美元。

良性攝護腺增生（BPH）或良性攝護腺肥大是指導致尿道阻塞的攝護腺非癌性增大。這種情況會導致尿滯留困難、膀胱結石、因過度充盈而導致的尿失禁、膀胱敏感性增加以及尿路感染。 BPH 的一些常用治療替代方案包括處方藥、主動觀察或監測、單一藥物和聯合療法、植物療法以及微創 (MI) 和侵入性手術。這些手術通常透過電切鏡、射頻消融裝置、泌尿外科雷射、前列腺支架和植入物等設備進行。

全球泌尿系統疾病的盛行率不斷上升，是創造積極市場前景的關鍵因素之一。此外，老年人口的增加更容易患此類嚴重疾病，這也推動了市場的成長。醫療保健提供者使用 α 受體阻斷劑透過放鬆前列腺肌肉和控制患者血壓來控制 BPH。與此一致的是，大眾的健康意識和對可用治療替代方案的認知不斷提高也促進了市場的成長。此外，各種進步，例如作為一種有效治療方法的經尿道前列腺電切（TURP）的發展，也起到了其他生長誘導因素的作用。 TURP 是一種內視鏡電外科手術，涉及切除前列腺的一部分以減少異常生長引起的阻塞。其他因素，包括個人醫療保健支出能力的提高，以及醫療保健基礎設施的顯著改善，特別是在發展中國家，預計將進一步推動市場。

本報告回答的關鍵問題：

  • 迄今為止，全球良性前列腺增生治療市場表現如何，未來幾年將如何表現？
  • COVID-19對全球良性攝護腺增生治療市場有何影響？
  • 主要區域市場有哪些？
  • 根據治療類型的市場分類是怎樣的？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球良性攝護腺增生治療市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球良性攝護腺增生治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依治療類型

  • 藥品類別
    • 市場趨勢
    • 主要類型
      • α-阻斷劑
      • 5-α-還原酶抑制劑 (5-ARIs)
      • 磷酸二酯酶 5 酶抑制劑
      • 其他
    • 市場預測
  • 微創手術
    • 市場趨勢
    • 主要類型
      • 經尿道攝護腺電切術 (TURP)
      • 經尿道攝護腺切開術 (TUIP)
      • 經尿道微波熱療 (TUMT)
      • 機器人手術
      • 前列腺尿道提升術
      • 其他
    • 市場預測
  • 雷射治療
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 8 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 9 章：價值鏈分析

第 10 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 11 章：價格分析

第 12 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Allergan plc (AbbVie Inc.)
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Boehringer Ingelheim GmbH (CH Boehringer Sohn AG & Ko. KG)
    • Boston Scientific Corporation
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A2898

The global benign prostatic hyperplasia treatment market size reached US$ 11.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.1 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy refers to the non-cancerous enlargement of the prostate gland that causes blockage in the urethra. This condition causes difficulties in urine retention, bladder stones, incontinence due to overfilling, increased sensitivity of the bladder and infections in the urinary tract. Some of the commonly used treatment alternatives for BPH include prescription drugs, active observation or surveillance, mono drug and combined therapies, phytotherapies and minimally invasive (MI) and invasive surgeries. These surgeries are usually conducted through devices, such as resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents and implants.

The increasing prevalence of urological disorders across the globe represents one of the key factors creating a positive outlook for the market. Furthermore, the rising geriatric population, which is more susceptible to such critical ailments, is providing a boost to the market growth. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling the blood pressure of the patient. In line with this, rising health consciousness and awareness among the masses regarding the available treatment alternatives are also contributing to the market growth. Additionally, various advancements, such as the development of transurethral resection of the prostate (TURP) as an effective treatment procedure, are acting as other growth-inducing factors. TURP is an endoscopic electrosurgical procedure that involves removing a portion of the prostate gland to reduce obstruction caused by the abnormal growth. Other factors, including rising healthcare expenditure capacities of individuals, along with significant improvements in the healthcare infrastructure, especially in the developing countries, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global benign prostatic hyperplasia treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type.

Breakup by Treatment Type:

Drug Class

Alpha-Blockers

5-Alpha-reductase Inhibitors (5-ARIs)

Phosphodiesterase-5 Enzyme Inhibitors

Others

Minimally Invasive Surgeries

Transurethral Resection of the Prostate (TURP)

Transurethral Incision of the Prostate (TUIP)

Transurethral Microwave Thermotherapy (TUMT)

Robotic Surgeries

Prostatic Urethral Lifts

Others

Laser Therapy

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global benign prostatic hyperplasia treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global benign prostatic hyperplasia treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global benign prostatic hyperplasia treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Benign Prostatic Hyperplasia Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Drug Class
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Alpha-Blockers
      • 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
      • 6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Minimally Invasive Surgeries
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2 Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.4 Robotic Surgeries
      • 6.2.2.5 Prostatic Urethral Lifts
      • 6.2.2.6 Others
    • 6.2.3 Market Forecast
  • 6.3 Laser Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 United States
      • 7.1.1.1 Market Trends
      • 7.1.1.2 Market Forecast
    • 7.1.2 Canada
      • 7.1.2.1 Market Trends
      • 7.1.2.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 China
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Forecast
    • 7.2.2 Japan
      • 7.2.2.1 Market Trends
      • 7.2.2.2 Market Forecast
    • 7.2.3 India
      • 7.2.3.1 Market Trends
      • 7.2.3.2 Market Forecast
    • 7.2.4 South Korea
      • 7.2.4.1 Market Trends
      • 7.2.4.2 Market Forecast
    • 7.2.5 Australia
      • 7.2.5.1 Market Trends
      • 7.2.5.2 Market Forecast
    • 7.2.6 Indonesia
      • 7.2.6.1 Market Trends
      • 7.2.6.2 Market Forecast
    • 7.2.7 Others
      • 7.2.7.1 Market Trends
      • 7.2.7.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Forecast
    • 7.3.2 France
      • 7.3.2.1 Market Trends
      • 7.3.2.2 Market Forecast
    • 7.3.3 United Kingdom
      • 7.3.3.1 Market Trends
      • 7.3.3.2 Market Forecast
    • 7.3.4 Italy
      • 7.3.4.1 Market Trends
      • 7.3.4.2 Market Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Trends
      • 7.3.5.2 Market Forecast
    • 7.3.6 Russia
      • 7.3.6.1 Market Trends
      • 7.3.6.2 Market Forecast
    • 7.3.7 Others
      • 7.3.7.1 Market Trends
      • 7.3.7.2 Market Forecast
  • 7.4 Latin America
    • 7.4.1 Brazil
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Forecast
    • 7.4.2 Mexico
      • 7.4.2.1 Market Trends
      • 7.4.2.2 Market Forecast
    • 7.4.3 Others
      • 7.4.3.1 Market Trends
      • 7.4.3.2 Market Forecast
  • 7.5 Middle East and Africa
    • 7.5.1 Market Trends
    • 7.5.2 Market Breakup by Country
    • 7.5.3 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Key Players
  • 12.3 Profiles of Key Players
    • 12.3.1 Abbott Laboratories
      • 12.3.1.1 Company Overview
      • 12.3.1.2 Product Portfolio
      • 12.3.1.3 Financials
      • 12.3.1.4 SWOT Analysis
    • 12.3.2 Allergan plc (AbbVie Inc.)
      • 12.3.2.1 Company Overview
      • 12.3.2.2 Product Portfolio
      • 12.3.2.3 Financials
      • 12.3.2.4 SWOT Analysis
    • 12.3.3 Asahi Kasei Corporation
      • 12.3.3.1 Company Overview
      • 12.3.3.2 Product Portfolio
      • 12.3.3.3 Financials
      • 12.3.3.4 SWOT Analysis
    • 12.3.4 Astellas Pharma Inc.
      • 12.3.4.1 Company Overview
      • 12.3.4.2 Product Portfolio
      • 12.3.4.3 Financials
      • 12.3.4.4 SWOT Analysis
    • 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
      • 12.3.5.1 Company Overview
      • 12.3.5.2 Product Portfolio
      • 12.3.5.3 SWOT Analysis
    • 12.3.6 Boston Scientific Corporation
      • 12.3.6.1 Company Overview
      • 12.3.6.2 Product Portfolio
      • 12.3.6.3 Financials
      • 12.3.6.4 SWOT Analysis
    • 12.3.7 GlaxoSmithKline Plc
      • 12.3.7.1 Company Overview
      • 12.3.7.2 Product Portfolio
      • 12.3.7.3 Financials
      • 12.3.7.4 SWOT Analysis
    • 12.3.8 Pfizer Inc.
      • 12.3.8.1 Company Overview
      • 12.3.8.2 Product Portfolio
      • 12.3.8.3 Financials
      • 12.3.8.4 SWOT Analysis
    • 12.3.9 Sanofi S.A.
      • 12.3.9.1 Company Overview
      • 12.3.9.2 Product Portfolio
      • 12.3.9.3 Financials
      • 12.3.9.4 SWOT Analysis
    • 12.3.10 Teva Pharmaceutical Industries Ltd.
      • 12.3.10.1 Company Overview
      • 12.3.10.2 Product Portfolio
      • 12.3.10.3 Financials
      • 12.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Benign Prostatic Hyperplasia Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2023
  • Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2023
  • Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Country (in %), 2023
  • Figure 62: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
  • Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
  • Figure 65: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Benign Prostatic Hyperplasia Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 4: Global: Benign Prostatic Hyperplasia Treatment Market: Competitive Structure
  • Table 5: Global: Benign Prostatic Hyperplasia Treatment Market: Key Players